Health and Healthcare
5864 Articles
247 Wall St. could not help but notice four analyst calls this past week in which upside of 50% to…
The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks…
Akebia Therapeutics shares hit a new 52-week low after the company announced the pricing for its secondary offering.
While few people may want to admit it, but more and more cosmetic surgery and treatments are being done every…
On the close Friday, the NYSE Arca Biotechnology Index is set for a rebalance. These four stocks that could see…
UnitedHealth Group reported better-than-expected first-quarter financial results Thursday before the markets opened.
Johnson & Johnson reported better-than-expected first-quarter fiscal 2015 results before markets opened Tuesday morning.
Celgene is one of the world's top biotech stocks now, and its market cap is nearly $100 billion. The company…
The March 31 short interest data have been compared with the March 13 figures, and for most of the selected…
Independent research firm Argus has weighed in on Mylan and Perrigo prior to the acquisition.
In a new research report, Cowen analysts focus on three life science stocks that they think could beat current consensus…
Gilead Sciences is a major biotech involved with the EASL conference, and two analysts are calling heads and tails in…
Generic drug maker Mylan has proposed to acquire rival Perrigo for $205 per share in cash and stock.
Rite Aid is scheduled to release its fiscal fourth-quarter financial results Wednesday morning before the markets open.
The newest hot stock in biotechnology is now giving everyone the chance to get a piece of it via an…
Our top personal finance-related articles today. Your wallet will thank you later.